Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ASBS 2010: Economy, Rise in Mastectomies Temper Minimally Invasive Advancements in Breast Care

Executive Summary

Surgeons attending the 11th annual meeting of the American Society of Breast Surgeons were perplexed by the reversal of the trend away from mastectomy and toward breast-conserving therapies. Advanced breast-conserving products were presented at the meeting; but with lowered revenue expectations that can ultimately be attributed to the economic woes of the past couple of years. High unemployment and the lack of health care coverage have prompted many women to delay or forego their yearly mammogram, and as a result, the numbers of biopsies, surgeries, and radiation therapy procedures have declined as well.

You may also be interested in...

SSI: Revolutionizing Breast Cancer Detection, but Slowly

Building off conventional ultrasound technology, France's SSI hopes to change the way breast cancer detection is done, reducing the number of unnecessary biopsies by employing elastography to register the stiffness of breast tissue. But as the company seeks to challenge a 3000 year old, low tech approach--manual palpation--company officials are proceeding slowly and are cautious about the claims they make for their technology's innovativeness.

Frontiers in Breast Cancer Research, Part II: Developments in Partial Breast Irradiation and Tumor Ablation

As the use of breast conserving lumpectomy expands as a treatment for early-stage breast cancer, interest has surged in alternatives to whole breast irradiation. Follow-on radiation treatment is crucial to the success of this therapy, but a significant number of women are either unable or unwilling to undergo the typical treatment course involving five to seven weeks of daily radiation therapy. The device industry is responding with technologies aimed at delivering post-lumpectomy radiation therapy in a more convenient, potentially safer way.

New Frontiers in Breast Cancer Research, Part I: Advances in Imaging and Diagnosis

After years of working for a "cure" for breast cancer, researchers have come to realize the enormity of the task. Although therapeutic advances are making it possible for women with advanced breast cancer to live longer, more comfortable lives, scientists still have a long way to go before they fully understand this complex disease. At this year's Society of Surgical Oncology's annual Cancer Symposium, researchers zeroed in on several key areas that could eventually unlock new methods of controlling, and possibly eliminating, this all too pervasive threat.

Related Content


Related Companies

Related Deals

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts